Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799

被引：0

作者：

Reck, M. ^{[1
]}

Lee, K. H. ^{[2
]}

Frost, N. ^{[3
,4
,5
,6
]}

Kowalski, D. M. ^{[7
]}

Breder, V. ^{[8
]}

Pollock, T. ^{[9
]}

Reguart, N. ^{[10
]}

Houghton, B. ^{[11
]}

Quantin, X. ^{[12
]}

Keller, S. M. ^{[13
]}

Liu, H. ^{[13
]}

Piperdi, B. ^{[13
]}

Jabbour, S. K. ^{[14
]}

机构：

[1] German Ctr Lung Res, Airway Res Ctr North, Lungenclin, Grosshansdorf, Germany

[2] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[3] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Berlin Inst Hlth, Berlin, Germany

[7] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[9] Southwestern Reg Med Ctr Inc, Canc Treatment Ctr Amer, Tulsa, OK USA

[10] Hosp Clin Barcelona, Barcelona, Spain

[11] Port Macquarie Base Hosp, Mid North Coast Canc Inst, Port Macquarie, NSW, Australia

[12] Montpellier Canc Inst, Dept Med Oncol, Montpellier, France

[13] Merck & Co Inc, Kenilworth, NJ USA

[14] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

nonesmall-cell lung cancer; Pembrolizumab; chemoradiation therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA02.03

引用

页码：S103 / S104

页数：2

共 50 条

[1] Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799
Jabbour, S. K.
Lee, K. H.
Frost, N.
Breder, V.
Kowalski, D.
Alawin, I.
Levchenko, E.
Reguart, N.
Martinez-Marti, A.
Houghton, B.
Paoli, J. B.
Safina, S.
Park, K.
Komiya, T.
Sanford, A.
Boolell, V.
Liu, H.
Samkari, A.
Keller, S.
Reck, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S9 - S10
[2] KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Breder, Valeriy Vladimirovich
Kowalski, Dariusz M.
Alawin, Issam Abdelkarim
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufia
Park, Keunchil
Komiya, Takefumi
Sanford, Amy
Boolell, Vishal
Liu, Hong
Samkari, Ayman
Keller, Steven M.
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Pembrolizumab plus Concurrent Chemoradiation Therapy (cCRT) for Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 2-Year Update
Jabbour, S. K.
Lee, K. H.
Frost, N.
Breder, V.
Kowalski, D.
Levchenko, E.
Reguart, N.
Martinez-Marti, A.
Houghton, B.
Paoli, J. B.
Safina, S.
Komiya, T.
Sanford, A.
Liu, H.
Song, A. J.
Keller, S.
Reck, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S29 - S30
[4] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Kowalski, Dariusz
Breder, Valeriy Vladimirovich
Pollock, Theodore
Reguart, Noemi
Houghton, Baerin
Quantin, Xavier
Keller, Steven M.
Liu, Hong
Piperdi, Bilal
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
Reck, Martin
Lee, Ki Hyeong
Frost, Nicolaj
Breder, Valeriy Vladimirovich
Kowalski, Dariusz
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufiia
Komiya, Takefumi
Sanford, Amy
Liu, Hong
Song, Andrew J.
Keller, Steven M.
Jabbour, Salma K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer The Phase 2 KEYNOTE-799 Nonrandomized Trial
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nikolaj
Breder, Valeriy
Kowalski, Dariusz M.
Pollock, Theodore
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufia
Park, Keunchil
Komiya, Takefumi
Sanford, Amy
Boolell, Vishal
Liu, Hong
Samkari, Ayman
Keller, Steven M.
Reck, Martin
JAMA ONCOLOGY, 2021, 7 (09) : 1351 - 1359
[7] Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage Ill non small-cell lung cancer (NSCLC): KEYNOTE-799.
Jabbour, Salma K.
Park, Keunchil
Cohn, Dosinda
Liu, Hong
Keller, Steven M.
Kowalski, Dariusz M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non-small-cell lung cancer (NSCLC): From KEYNOTE-799
Reck, Martin
Lee, Ki Hyeong
Frost, Nikolaj
Breder, Valeriy Vladimirovich
Kowalski, Dariusz M.
Levchenko, Evgeny
Reguart, Noemi
Martinez-Marti, Alex
Houghton, Baerin
Paoli, Jean-Baptiste
Safina, Sufiia
Liu, Hong
Novinskiy, Vladimir
Dettman, E. J.
Kobie, Julie
Jabbour, Salma K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Combination of radiotherapy and chemotherapy in locally advanced NSCLC
Kepka, Lucyna
Sprawka, Arkadiusz
Casas, Francesc
Abdel-Wahab, Sherif
Agarwal, Jai Prakash
Jeremic, Branislav
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) : 1389 - 1403
[10] Chemotherapy or radiotherapy for palliation of locally advanced NSCLC?
Sundstrom, S.
RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S4 - S4

← 1 2 3 4 5 →